Recent blog posts
Phase 2/3 Study Shows Nipocalimab Effectively Controls Symptoms in Teenagers with Generalized Myasthenia Gravis
Latest Hotspot
4 min read
Phase 2/3 Study Shows Nipocalimab Effectively Controls Symptoms in Teenagers with Generalized Myasthenia Gravis
17 October 2024
In a Phase 2/3 study, nipocalimab effectively controls symptoms in teenagers with generalized myasthenia gravis.
Read →
Beacon Therapeutics Announces Positive 24-Month Phase 2 SKYLINE Study Results for AGTC-501 in X-Linked Retinitis Pigmentosa
Latest Hotspot
3 min read
Beacon Therapeutics Announces Positive 24-Month Phase 2 SKYLINE Study Results for AGTC-501 in X-Linked Retinitis Pigmentosa
17 October 2024
Beacon Therapeutics Reports Favorable 24-Month Results from Phase 2 SKYLINE Study of AGTC-501 in X-Linked Retinitis Pigmentosa Patients.
Read →
Topas Therapeutics Reports Positive Phase 2a Trial Results for TPM502 in Celiac Disease Patients
Latest Hotspot
3 min read
Topas Therapeutics Reports Positive Phase 2a Trial Results for TPM502 in Celiac Disease Patients
17 October 2024
Topas Therapeutics released encouraging top-line outcomes from a Phase 2a study examining their leading candidate, TPM502.
Read →
Circle Pharma Launches Phase 1 Trial of CID-078, Oral Inhibitor for Advanced Solid Tumors
Latest Hotspot
4 min read
Circle Pharma Launches Phase 1 Trial of CID-078, Oral Inhibitor for Advanced Solid Tumors
17 October 2024
Circle Pharma Begins Phase 1 Clinical Trial with CID-078, an Oral Cyclin A/B RxL Inhibitor, Administered to Initial Patients for Advanced Solid Tumors.
Read →
Update on Transgene's Phase II Trial of TG4001 Cancer Vaccine for HPV16-Positive Cervical and Anogenital Cancers
Latest Hotspot
4 min read
Update on Transgene's Phase II Trial of TG4001 Cancer Vaccine for HPV16-Positive Cervical and Anogenital Cancers
17 October 2024
Transgene updates on Phase II trial for TG4001 cancer vaccine targeting recurrent or metastatic HPV16-positive cervical and anogenital cancers.
Read →
GSK Reports Positive Phase III Results from ANCHOR Trials on Depemokimab for Chronic Sinusitis with Nasal Polyps
Latest Hotspot
3 min read
GSK Reports Positive Phase III Results from ANCHOR Trials on Depemokimab for Chronic Sinusitis with Nasal Polyps
15 October 2024
GSK shares favorable phase III findings from ANCHOR trials on depemokimab for chronic rhinosinusitis with nasal polyps.
Read →
FDA Approves SystImmune's IND Application for BL-M11D1 in Relapsed Acute Myeloid Leukemia
Latest Hotspot
3 min read
FDA Approves SystImmune's IND Application for BL-M11D1 in Relapsed Acute Myeloid Leukemia
15 October 2024
SystImmune, Inc. has received FDA approval for its IND application regarding BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia.
Read →
Repare Therapeutics Begins Phase 1 Trial Dosing with RP-3467, a Polθ ATPase Inhibitor
Latest Hotspot
3 min read
Repare Therapeutics Begins Phase 1 Trial Dosing with RP-3467, a Polθ ATPase Inhibitor
15 October 2024
Repare Therapeutics has initiated dosing for the first patient in a Phase 1 clinical trial of RP-3467, an inhibitor of Polθ ATPase.
Read →
The US FDA has given approval to Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a biosimilar for STELARA®
Latest Hotspot
3 min read
The US FDA has given approval to Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a biosimilar for STELARA®
15 October 2024
Dong-A ST declared that its biosimilar Imuldosa™ (ustekinumab-srlf/DMB-3115), which references Stelara®, has received approval from the U.S. Food and Drug Administration (FDA).
Read →
FDA Approves Pfizer’s HYMPAVZI™ for Hemophilia A and B in Adults and Teens Without Inhibitors
Latest Hotspot
4 min read
FDA Approves Pfizer’s HYMPAVZI™ for Hemophilia A and B in Adults and Teens Without Inhibitors
15 October 2024
The FDA has authorized Pfizer's HYMPAVZI™ (marstacimab-hncq) for use in adults and teens with hemophilia A or B who do not have inhibitors.
Read →
Sutro Biopharma showcases cutting-edge ADC technology and upcoming projects at research event
Latest Hotspot
3 min read
Sutro Biopharma showcases cutting-edge ADC technology and upcoming projects at research event
15 October 2024
Sutro Biopharma, is a clinical-stage oncology firm that specializes in innovative, site-specific antibody-drug conjugates (ADCs).
Read →
FDA Approves Genentech's Itovebi for Specific Advanced Breast Cancer
Latest Hotspot
4 min read
FDA Approves Genentech's Itovebi for Specific Advanced Breast Cancer
15 October 2024
The FDA has sanctioned Genentech's Itovebi, a focused therapy for advanced hormone receptor-positive, HER2-negative breast cancer that carries a PIK3CA mutation.
Read →